1878sek
-3,5 %
Date:2026-01-20Time:18:00:00Latest report:Q3-2025List:Small CapTicker:CINPHA
Market Cap:890 msekEnterprise Value:358 msekNet Sales:48,4 msekEarnings:-177,0 msekEmployees:0ISIN:SE0020388577

Ratios

10-year key figure history for Cinclus Pharma turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Cinclus Pharma with index and moving average MA50 and MA200.

Stockprice:18,78
MA50:18,04
MA200:15,83
Price/MA200:18,6 %
RSI (14):53,2
Price/MA50:4,1 %

Description

Cinclus Pharma is a Swedish clinical-stage pharmaceutical company. The company is active in the development of molecules for the treatment of acid-related diseases. The company's lead drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and is headquartered in Stockholm, Sweden.

Pharmaceuticals